Ann: Changes to the Board of Directors, page-6

I should clarify that I didnt Intend any disrespect of the other board members, I am assuming that they absolutely understand where we are at and the potential that may be unfolding. My point was that Robert seemed to be the one who has been involved with multiple pharma research projects and as such I thought through his experience whilst at Janssen amongst others he had worked in areas that we might affect and had seen something he liked. Hopefully that is still the case, but that takes nothing away from the seemingly laser like focus current directors now seem to have on real commercialisation.